Table 1.

Clinical characteristics of the patients who experienced relapse of MRSA bacteremia after vancomycin treatment

Case	Bacteremia no.	Patient age (yr)	Sourcea	TEE performeda,b	Treatment length (days)a	Days to relapse	Days of bacteremia/outcome	MIC (μg/ml)d
								Vanc	Dapto	Linezolid
1	1	62	Unknown	Yes	14		8	1.5	0.5	1.5
	2					14	1/death	1.5	0.5	0.75
2	1	64	Skin	Yesc	17		16	0.75	0.75	1
	2					16	6/death	0.5	0.5	0.5
3	1	51	Unknown	Yes	13		1	1.5	0.38	0.38
	2					102	15	2	0.5	0.38
4	1	58	Catheter	Yes	28		14	2	0.75	0.5
	2					20	22/death	3	1	0.75
5	1	62	Skin	No	17		5	1.5	0.19	1
	2					120	6	3	1	0.75
6	1	67	Unknown	Yes	30		19	1.5	0.38	0.75
	2					14	10	1.5	0.25	0.75
7	1	20	Unknown	Yes	14		1	1.5	0.38	0.75
	2					36	3	1.5	0.25	0.5
8	1	27	Respiratory	Yes	14		10	1.5	0.38	1
	2					23	20	1.5	0.38	0.75
9	1	32	Unknown	Yes	18		4	1.5	0.38	0.75
	2					41	5	1.5	0.25	0.5
10	1	18	Unknown	No	19		2	1.5	0.25	0.75
	2					45	5	1.5	0.38	0.75
	3					35	4	2	0.38	0.75
11	1	66	Multiple sites	Yes	22		14	1.5	0.38	0.75
	2					79	16/death	1.5	0.5	2

^aRefers to the initial bacteremic episode.

^bTEE, transesophageal echocardiogram.

^cEndocarditis was diagnosed on the second episode of bacteremia for case 2. No other cases of endocarditis were detected.

^dVanc, vancomycin; Dapto, daptomycin.